Publications by authors named "Paul Elzinga"

Claim this Profile
T
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Chetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, David Frennesson, Peiying Liu, Paul A Elzinga

Bioorg Med Chem Lett· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.
Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, Paul A Elzinga

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.
Satheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, Ramesh Sistla, Durgarao Kantheti, Paul Elzinga

ACS Med Chem Lett· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Scott H Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G Batt, Ling Li, Paul A Elzinga

J Med Chem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Imidazo[1,2-]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.
Chunjian Liu, James Lin, Ryan Moslin, John S Tokarski, Jodi Muckelbauer, Paul Elzinga

ACS Med Chem Lett· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A polychromatic turbidity microplate assay to distinguish discovery stage drug molecules with beneficial precipitation properties.
John Morrison, Michelle Nophsker, Paul Elzinga, Maria Donoso, Hyunsoo Park

Int J Pharm· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.
Audris Huang, Lata Jayaraman, Aberra Fura, Gregory D Vite, George L Trainor, Paul A Elzinga

ACS Med Chem Lett· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid throughput screening of apparent KSP values for weakly basic drugs using 96-well format.
Jeremy Guo, Paul A Elzinga, Michael J Hageman, James N Herron

J Pharm Sci· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid throughput solubility screening method for BCS class II drugs in animal GI fluids and simulated human GI fluids using a 96-well format.
Jeremy Guo, Paul A Elzinga, Michael J Hageman, James N Herron

J Pharm Sci· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis